Ustekinumab in hidradenitis suppurativa: Clinical results and a search for potential biomarkers in serum

British Journal of Dermatology

Volumn 174, Issue 4, 2016, Pages 839-846

  Blok, J L ^a   Li, K ^b   Brodmerkel, C ^b   Horvatovich P ^c   Jonkman, M F ^a   Horvath B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; CORTICOSTEROID; ETANERCEPT; FOLLITROPIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2 RECEPTOR; ISOTRETINOIN; LEUKOTRIENE A4 HYDROLASE; LUTEINIZING HORMONE; PREDNISOLONE; RESORCINOL; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; CYTOKINE; DERMATOLOGICAL AGENT; EPOXIDE HYDROLASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MALE; MIDDLE AGED; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; CLINICAL TRIAL; HIDRADENITIS SUPPURATIVA; METABOLISM; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BIOMARKERS; CHORIONIC GONADOTROPIN; CYTOKINES; DERMATOLOGIC AGENTS; EPOXIDE HYDROLASES; FEMALE; FOLLICLE STIMULATING HORMONE; HIDRADENITIS SUPPURATIVA; HUMANS; INJECTIONS, SUBCUTANEOUS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; USTEKINUMAB; YOUNG ADULT;

EID: 84958087745     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14338     Document Type: Article

References (37)

1. Revuz J,. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-98.
2. Hurley HJ,. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic Surgery (Roenigh RK. (, Roenigk HH, eds), New York: Marcel Dekker, 1989, 729-39.
3. Matusiak L, Bieniek A, Szepietowski JC,. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90: 264-8.
4. Wolkenstein P, Loundou A, Barrau K, et al,. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-3.
5. Alikhan A, Lynch PJ, Eisen DB,. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-61.
6. Miller IM, Ellervik C, Vinding GR, et al,. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150: 1273-80.
7. Danby FW, Jemec GB, Marsch WC, von Laffert M,. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013; 168: 1034-9.
8. van der Zee HH, de Ruiter L, van den Broecke DG, et al,. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-8.
9. Schlapbach C, Hanni T, Yawalkar N, Hunger RE,. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-8.
10. Zouboulis CC, Desai N, Emtestam L, et al,. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-44.
11. Blok JL, van Hattem S, Jonkman MF, Horvath B,. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 2013; 168: 243-52.
12. Kimball AB, Kerdel F, Adams D, et al,. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846-55.
13. Benson JM, Peritt D, Scallon BJ, et al,. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011; 3: 535-45.
14. Giatrakos S, Huse K, Kanni T, et al,. Haplotypes of IL-12Rβ1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine 2013; 62: 297-301.
15. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
16. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
17. Sharon VR, Garcia MS, Bagheri S, et al,. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92: 320-1.
18. Gulliver WP, Jemec GB, Baker KA,. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26: 911-14.
19. Baerveldt EM, Kappen JH, Thio HB, et al,. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 2013; 72: 626-7.
20. Martin-Ezquerra G, Masferrer E, Masferrer-Niubó M, et al,. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015; 29: 56-60.
21. Santos-Pérez MI, García-Rodicio S, Del Olmo-Revuelto MA, Pozo-Román T,. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr 2014; 105: 720-2.
22. Sartorius K, Emtestam L, Jemec GB, Lapins J,. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-9.
23. Prinsen CA, Lindeboom R, de Korte J,. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol 2011; 131: 1945-7.
24. Hongbo Y, Thomas CL, Harrison MA, et al,. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-64.
25. Basra MK, Fenech R, Gatt RM, et al,. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
26. Kimball AB, Sobell JM, Zouboulis CC, et al,. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 2015; DOI: 10.1111/jdv.13216.
27. van Rappard DC, Leenarts MF, Meijerink-van't Oost L, Mekkes JR,. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 2012; 23: 284-9.
28. Savva A, Kanni T, Damoraki G, et al,. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 2013; 168: 311-17.
29. Fardet L, Dupuy A, Kerob D, et al,. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-8.
30. Sandborn WJ, Gasink C, Gao LL, et al,. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
31. Ryu H, Chung Y,. Regulation of IL-17 in atherosclerosis and related autoimmunity. Cytokine 2015; 74: 219-27.
32. Matusiak L, Bieniek A, Szepietowski JC,. Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 2009; 14: 432-7.
33. Wieland CW, Vogl T, Ordelman A, et al,. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity? Br J Dermatol 2013; 168: 1252-8.
34. Cemil BC, Cengiz FP, Atas H, et al,. Sex hormones in male psoriasis patients and their correlation with the Psoriasis Area and Severity Index. J Dermatol 2015; 42: 500-3.
35. Mortimer PS, Dawber RP, Gales MA, Moore RA,. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 1986; 292: 245-8.
36. Harrison BJ, Kumar S, Read GF, et al,. Hidradenitis suppurativa: evidence for an endocrine abnormality. Br J Surg 1985; 72: 1002-4.
37. Snelgrove RJ,. Leukotriene A4 hydrolase: an anti-inflammatory role for a proinflammatory enzyme. Thorax 2011; 66: 550-1.